Natural Product (NP) Details
| General Information of the NP (ID: NP6785) | |||||
|---|---|---|---|---|---|
| Name |
Brucine
|
||||
| Synonyms |
BRUCINE; 357-57-3; 10,11-Dimethoxystrychnine; Brucinum; (-)-Brucine; l-Brucine; 2,3-Dimethoxystrychnine; 2,3-Dimethoxystrychnidin-10-one; 10,11-Dimethystrychnine; UNII-6NG17YCK6H; Brucina; Brucin; 6NG17YCK6H; Brucine alkaloid; CHEBI:3193; Dimethoxy strychnine; Bruzin; 2,3-Dimethoxy-strychnine; RCRA waste number P018; DSSTox_RID_77490; DSSTox_GSID_24662; Strychnine, 2,3-dimethoxy-; 145428-94-0; Brucin [German]; Brucina [Italian]; (4aR,4a1R,5aS,8aR,8a1S,15aS)-10,11-dimethoxy-2,4a,4a1,5,5a,7,8,8a1,15,15a-decahydro-14H-4,6-methanoindolo[3,2,1-ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinolin-14-one; CAS-357-57-3; SMR000112281; DSSTox_CID_4662; 10,11-dimethoxy strychnine; CCRIS 4754; HSDB 307; anhydrous brucine; Bisdesmethylbrucin; Brucine Anhydrous; UN 1570; NCGC00094861-01; (4aR,5aS,8aR,13aS,15aS,15bR)-10,11-dimethoxy-4a,5,5a,7,8,13a,15,15a,15b,16-decahydro-2H-4,6-methanoindolo[3,2,1-ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinoline-14-one; EINECS 206-614-7; UN1570; PubChem7945; RCRA waste no. P018; Brucine, anhydrous, 98%; GTPL342; MLS000515808; MLS001424166; SCHEMBL113229; CHEMBL501756; MEGxp0_001865; DTXSID2024662; ACon1_001990; Brucine [UN1570] [Poison]; HMS2052O03; HMS2268L16; ZINC1069090; Tox21_111349; Tox21_302174; BDBM50401037; MFCD00005942; AKOS015955678; AKOS024282466; CCG-101078; MCULE-9524496694; NC00328; NSC 757797; NCGC00255253-01; NCGC00263445-02; NCGC00384497-01; M127; B0670; B0946; C09084; Brucine - CASMI2016 Category 1 - Challenge 9; Q411022; SR-01000712407; Q-100426; SR-01000712407-5; BRD-K68077509-001-01-6; Brucine, European Pharmacopoeia (EP) Reference Standard; (1R,11S,18S,20R,21R,22S)-4,5-dimethoxy-12-oxa-8,17-diazaheptacyclo[15.5.2.0^{1,18}.0^{2,7}.0^{8,22}.0^{11,21}.0^{15,20}]tetracosa-2(7),3,5,14-tetraen-9-one
Click to Show/Hide
|
||||
| Species Origin | Strchnos icaja ... | Click to Show/Hide | |||
| Strchnos icaja | |||||
| Disease | Hepatocellular carcinoma [ICD-11: 2C12] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| ADMET Property |
Absporption
Caco-2 Permeability
-4.728
MDCK Permeability
-4.859
PAMPA
- - -
HIA
- - -
Distribution
VDss
0.056
PPB
41.3%
BBB
- - -
Metabolism
CYP1A2 inhibitor
- - -
CYP1A2 substrate
+++
CYP2C19 inhibitor
- - -
CYP2C19 substrate
+++
CYP2C9 inhibitor
- - -
CYP2C9 substrate
- - -
CYP2D6 inhibitor
- - -
CYP2D6 substrate
++
CYP3A4 inhibitor
++
CYP3A4 substrate
+++
CYP2B6 inhibitor
+++
CYP2B6 substrate
- - -
CYP2C8 inhibitor
- - -
HLM Stability
++
Excretion
CLplasma
7.134
T1/2
2.567
Toxicity
DILI
- -
Rat Oral Acute Toxicity
+
FDAMDD
+
Respiratory
+
Human Hepatotoxicity
++
Ototoxicity
++
Drug-induced Nephrotoxicity
++
Drug-induced Neurotoxicity
+
Hematotoxicity
++
Genotoxicity
+++
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C23H26N2O4
|
||||
| PubChem CID | |||||
| Canonical SMILES |
COC1=C(C=C2C(=C1)C34CCN5C3CC6C7C4N2C(=O)CC7OCC=C6C5)OC
|
||||
| InChI |
1S/C23H26N2O4/c1-27-16-8-14-15(9-17(16)28-2)25-20(26)10-18-21-13-7-19-23(14,22(21)25)4-5-24(19)11-12(13)3-6-29-18/h3,8-9,13,18-19,21-22H,4-7,10-11H2,1-2H3/t13-,18-,19-,21-,22-,23+/m0/s1
|
||||
| InChIKey |
RRKTZKIUPZVBMF-IBTVXLQLSA-N
|
||||
| CAS Number |
CAS 357-57-3
|
||||
| ChEBI ID | |||||
| Herb ID | |||||
| SymMap ID | |||||
| TCMSP ID | |||||
| TTD Drug ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Gemcitabine | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Brucine, either individually or in combination, but not gemcitabine, inhibited NF-kB subunit (p65) expression in MCF-7 cells. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Muscarinic acetylcholine receptor M3 (CHRM3) | Molecule Info | [3] | |
| KEGG Pathway | Calcium signaling pathway | Click to Show/Hide | ||
| 2 | Neuroactive ligand-receptor interaction | |||
| 3 | Cholinergic synapse | |||
| 4 | Regulation of actin cytoskeleton | |||
| 5 | Insulin secretion | |||
| 6 | Salivary secretion | |||
| 7 | Gastric acid secretion | |||
| 8 | Pancreatic secretion | |||
| Panther Pathway | Alzheimer disease-amyloid secretase pathway | Click to Show/Hide | ||
| 2 | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||
| 3 | Muscarinic acetylcholine receptor 1 and 3 signaling pathway | |||
| Pathwhiz Pathway | Gastric Acid Production | Click to Show/Hide | ||
| Reactome | Muscarinic acetylcholine receptors | Click to Show/Hide | ||
| 2 | Acetylcholine regulates insulin secretion | |||
| 3 | G alpha (q) signalling events | |||
| WikiPathways | Monoamine GPCRs | Click to Show/Hide | ||
| 2 | Calcium Regulation in the Cardiac Cell | |||
| 3 | Regulation of Actin Cytoskeleton | |||
| 4 | GPCRs, Class A Rhodopsin-like | |||
| 5 | Gastrin-CREB signalling pathway via PKC and MAPK | |||
| 6 | Integration of energy metabolism | |||
| 7 | GPCR ligand binding | |||
| 8 | GPCR downstream signaling | |||
| 9 | GPCRs, Other | |||
